Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.
Denials are usually procedural rather than clinical, and the order that works reflects that. Get the denial reason in writing, because it names the criterion you failed. Then supply the documentation that criterion asks for — usually documented BMI with a comorbidity, or a failed prior therapy. Then appeal, and ask for a peer-to-peer review, because a prescriber talking to a reviewing clinician resolves a large fraction of denials that written appeals do not. Manufacturer copay assistance is separate and applies mainly to commercial insurance, and patient assistance programmes are means-tested rather than a discount.
Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.
So the question, as narrowly as I can put it: what actually works on a prior-authorisation denial, as opposed to the list of things that sound like they should work. Numbers rather than impressions, if you have them.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
Dr.RenalNash said:Denials are usually procedural rather than clinical, and the order that works reflects that.
Financial impact of cost and coverage weight loss beyond medication cost:
- Groceries: SAVED $202/month (eating less)
- Restaurants: SAVED $212/month (fewer meals out)
- Alcohol: SAVED $162/month (stopped drinking)
- Life insurance: Premium REDUCED by $32/month (lower BMI)
- Copays: SAVED $62/month (fewer BP/cholesterol meds)
Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.
Dr.RenalNash said:Denials are usually procedural rather than clinical, and the order that works reflects that.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemLarryQC_SD said:The affordability discussion here usually stops at individual tactics.
LarryQC_SD said:...my insurance denied cost and coverage coverage because...
Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:
- Document medical necessity (BMI, comorbidities, failed alternatives)
- Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
- Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
- Request peer-to-peer review between your doctor and the plan's medical director
- File external appeal with your state insurance department if internal appeal fails
Don't accept the first denial. The appeal process exists for a reason.
Dr.SurgeonPGH said:Financial impact of cost and coverage weight loss beyond medication cost: Groceries: SAVED $202/month (eating less) Restaurants: SAVED $212/month…
Same experience, arrived at from the opposite direction. Posting only so the count is not one.